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Abstract
Background: This study was conducted to determine the scale and the nature of the economic burden caused by strokes 
and to use the results as an evidential source for determining the allocation of South Korea stroke cases in 2015.
Methods: For research subjects, the study analyzed demographic characteristics and economic burden based on data 
from national health insurance (NHI) claims for inpatient and outpatient cases of ischemic stroke and hemorrhagic 
stroke in 2015 through the Health Insurance Review and Assessment Service (HIRA) and statistical data regarding 
cause of death from the Korea National Statistical Office (KNSO). This study, in order to estimate economic burden 
due to stroke, deduced the direct and indirect costs of illness caused by stroke, using cost-of-illness (COI) methods. The 
economic burden is divided into direct and indirect costs, and indirect cost is estimated by summing lost productivity 
measured in opportunity cost lost by medical disposition due to a specific disease and lost productivity due to premature 
death.
Results: The total economic burden in Korea due to stroke was US$6.855 billion, that due to ischemic stroke was 
US$3.658 billion, and that due to hemorrhagic stroke was US$3.197 billion. The average economic burden per stroke 
case was about US$7247.
Conclusion: The results of estimating the annual economic burden in all of Korea due to stroke will be used as an 
evidential source for preparing medical insurance policies, priorities, and plans for arranging medical resources for 
stroke as well as for determining effective prevention of the disease and related priorities in national health care policies.
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Implications for policy makers
• Determination of the scale and content of economic damage caused by stroke.
• The type of stroke occurring most frequently was ischemic stroke, at a rate about 8.8 times higher than that of hemorrhagic stroke.
• The economic burden in Korea due to stroke was US$6.855 billion.
• The average economic burden per stroke was about US$7247.
• It is expected that this data will be highly useful as an evidential source for preparing medical insurance policies, priorities, and plans.
Implications for the public
This study was conducted to determine the scale and the nature of the economic cost of stroke cases in South Korea in 2015. The aim of this study 
was to determine the economic costs associated with strokes suffered by South Korean patients from January 1, 2015 until December 31, 2015. The 
economic cost in Korea due to stroke was USD$6.855 billion, of which the cost of ischemic strokes was US$3.658 billion, and that of hemorrhagic 
strokes was US$3.197 billion. As a result of producing an estimate of the annual economic cost in the whole nation of Korea due to stroke, it is 
expected that this data will be highly useful as an evidential source for preparing medical insurance policies, priorities, and plans for arranging 
medical resources related to stroke.
Key Messages 
Background 
Stroke is a major disease as it is the third cause of death 
following cancer and heart diseases in Korea, and has been 
a leading cause of death in developed countries such as the 
United States and European countries.1 Two-thirds of patients 
survive but most of them have serious disabilities exceeding 
middle levels, requiring comprehensive rehabilitation 
therapies for recovery from neurological damage and loss of 
function. Stroke is a leading cause of long-term disabilities, 
and only one quarter of patients recover sufficiently to lead 
independent lives.2 As a result, about a half of patients become 
a burden to their families or society within one year.3
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In order to manage higher death rates and economic costs 
related to stroke, studies on cost-of-illness (COI) are ongoing 
in European countries and the United States. Economic COI 
studies are aimed at making policies for the distribution 
of resources used for preventing and treating diseases 
by suggesting medical costs used for treating diseases, 
transportation costs, care costs, disease morbidity costs, 
and productivity damage costs due to premature death with 
monetary units and representing effects of diseases on the 
national economy including individuals objectively and 
empirically.4
In 2013 the National Health Insurance Service (NHIS) of 
Korea established a standard big data database for researchers 
utilizing information regarding the history of treatments, 
health examinations, residence and premiums, and healthcare 
institutions. This consists of a standard cohort database for 
the population of a million, three databases related to rare 
diseases, and a database about health examinations. This 
data is offered for studies with public benefit. In Korea, the 
entire citizenry is insured under this single service, and a 
single insurance claim database was established, providing 
very good conditions for conducting COI of various diseases 
including stroke.1
In the case of the United States, more than US$22.8 billion 
was estimated as total annual direct costs due to stroke in 
the single year of 2009 when the rate of medical disposition 
related to the diseases was compared and measured.5 Studies 
from Sweden, Canada, the Netherlands, the United Kingdom, 
and New Zealand using data regarding the registration of 
patients into government systems, their management, and 
claims to insurance, along with recent studies from Germany 
and Japan estimating the burden of disease for stroke have 
been published.1 
Korean studies of COI, were made by Lim et al, regarding the 
estimation of the economic cost of stroke cases using data 
from claims to the Health Insurance Review and Assessment 
Service (HIRA), the single point in 2005, a decade ago.1 In 
Korea after 10 years, now, with dramatic aging and increasing 
occurrence of stroke, many patients have participated in 
rehabilitation therapies. However, compared to other fields, 
there have been few studies regarding the estimation of the 
economic cost of the medical disposition of stroke cases. 
Accordingly, it is necessary to conduct holistic studies 
regarding social costs and the scale used for the costs of 
medication, inpatient stays, outpatient visits, rehabilitation, 
nursing home and so forth with regards to stroke.
Methods
Selection of the Research Subjects and Definition of the 
Variables
As research data to estimate the economic cost of stroke, 
insurance claim data generated during 2015 in Korea showing 
for the number of inpatient or outpatient visits to medical 
institutions were used. The study analyzed demographic 
characteristics and economic cost based on the data from 
National Health Insurance (NHI) claims regarding inpatient 
or outpatient treatment where, among ICD-Codes, ischemic 
stroke (International Classification of Disease-10-Clinical 
Modification I63) (ICD-10-CM I63) and hemorrhagic stroke 
(ICD-10-CM I61) were indicated as the main diagnoses 
in 2015 cases by HIRA, and the statistical data regarding 
stroke as cause of death (Korean Standard Classification of 
Diseases, KCD I60-I69) by the Korea National Statistical 
Office (KNSO). 
In this study, in keeping with previous studies, the economic 
cost of stroke was divided into direct and indirect costs. The 
estimated direct medical cost consisted of outpatient visit 
cost, inpatient cost, medication cost, the cost for using the 
pharmacy, and assistive device cost while direct non-medical 
cost consisted of transportation cost and caregiver cost. 
Indirect cost included costs due to work loss and premature 
death.4,6-9
Selection of Research Data
This study, estimated economic cost due to stroke using 
a COI method. Economic cost is divided into direct and 
indirect costs,4 and indirect cost is estimated by summing lost 
productivity measured in opportunity cost lost by medical 
disposition due to a specific disease and lost productivity due 
to premature death.10,11 All the analysis regarding inpatient 
and outpatient stroke-related treatment is based on data from 
2015 (Supplementary file 1).
Statistical Analysis
The data analysis in the study was done by using SPSS 12.0, 
and frequency analysis was conducted. The analysis results 
were calculated using Excel.
Estimation of Direct Costs
In this study, treatment cost, one of the direct costs includes 
inpatient and outpatient costs analyzed according to age 
and gender for the appropriate disease codes (ICD-10-CM 
I61 and I63) in the main statistical data for 2015 at the NHI 
Corporation, with total treatment costs estimated by adding 
covered inpatient (outpatient) treatment costs and non-
covered inpatient (outpatient) treatment costs. Treatment 
costs recorded by NHI do not include the non-covered 
allotment paid by the individual but include the portion 
covered by NHI after the legally allotted portion is paid by 
the individual. Therefore, the non-covered allotment paid by 
the individual was estimated separately by applying the non-
covered allotment paid by the individual for inpatient and 
outpatient treatment during the year using research on current 
treatment costs for insured patients as seen below. 
To estimate the cost of assistive devices for stroke cases, 
the annual cost for a patient to keep an assistive device was 
multiplied by the number of stroke patients. The annual cost 
for a patient to keep an assistive device was determined by 
adopting the cost for 2010 indicated in Kim’s study, 241 512 
KRW (US$206) which was adjusted using the consumer price 
inflation rate,12 to determine a 2015 value, and that amount 
was multiplied by the number of stroke patients to estimate 
the cost. The total direct costs can be estimated by summing 
inpatient and outpatient treatment costs, medication costs and 
costs for using the pharmacy, costs for buying and keeping 
assistive devices, transportation costs, and caregiver costs.
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Direct non-medical cost is divided into transportation cost 
used for outpatient visits and caregiver cost. Transportation 
costs were calculated for outpatient treatments by multiplying 
the number of claims for outpatient visits by an average 
round-trip rate of 21 000 KRW per visit to determine the total 
estimated transportation cost.7,13 
For caregiver cost for inpatients, the average daily caregiver 
cost cited in the Intermediate Status of Model Project for 
Institutionalization of Hospital Caregiver Service by the 
Ministry of Health and Welfare (2010), the most recent data 
available was adjusted using the consumer price inflation rate 
to convert it to a 2015 value, and then it was multiplied by the 
number of inpatient days to estimate the total amount.7
Estimation of Indirect Cost
Indirect cost measures lost opportunity cost due to medical 
disposition or premature death and consists of the indirect 
COI due to loss of productivity and the indirect COI due 
to premature death.3 The former includes reductions in 
work income for lost hours or days due to outpatient visits 
or hospitalization related to diagnosis and treatment of a 
disease. Outpatient visits result in a different amount of 
lost work time from hospitalization, so the total cost was 
arrived at by calculating the two separately and adding them 
together. If a person has two outpatient visits in one day, they 
were counted as two separate visits. One outpatient visit was 
assumed to require one-third of a work day. Considering one 
outpatient visit as equivalent to 1/3 of a day with regard to lost 
productivity, three outpatient visits were same as one day’s 
hospitalization.13
Indirect Cost of Lost Productivity 
For the calculation of cost due to premature death, after 
calculating the number of deaths due to stroke by age, life 
expectancy of stroke cases (lost years),14 average annual 
expected income, and employment rate were multiplied to 
estimate the total cost. In these calculations, the ages between 
1 and 19 and after 70 were considered to have no income 
(Supplementary file 2).13
Costs Per Stroke Event
The average economic cost per stroke case was calculated by 
dividing the total cost excluding the cost of premature death 
by the number of patients, with the following estimation 
formula is as follows1:
Results 
The Characteristics and Current Status of the Research 
Subjects 
For the period of the analysis, from January 1, 2015 to 
December 31, 2015, the numbers of stroke events resulting 
in treatment who were treated in medical facilities in Korea 
covered by NHI was 515 848, 1.05% of the 49 088 000 total 
treated patients claimed for review and assessment in 2015. 
Their demographic features by gender, age and medical facility 
are as follows (Table 1). Gender, age, and ICD-10 show the 
number of stroke events, and disposition and medical facility 
show the number of visits. The gender distribution of those 
diagnosed as having suffered a stroke, included 277 641 male 
patients (53.82%) and 238 207 female patients (46.18%). With 
regard to the distribution of occurrence of stroke by age group, 
the highest share was for the ages from 70 to 79, with 178 504 
patients (34.60%). Regarding disposition, outpatient visits 
cases were 472 371 (78.48%), and hospitalization cases were 
129 513 (21.52%), the former being about 3.6 times as many 
as the latter. With regards to primary medical facilities used 
in the treatment of stroke cases, general hospitals were used 
by a total of 232 450 patients (39.54%), and tertiary hospitals 
by 187 263 patients (31.85%). In comparing the frequency 
of occurrence, ischemic stroke occurred in 463 147 patients 
(89.78%), about 8.8 times as many as the 52 701 patients 
(10.22%) with haemorrhage stroke. ‘Hospitalization’ is the 
number of inpatient visits. If a patient made two inpatient 
visits in 2015, does ‘hospitalization’ count them as two. The 
medical facility is the same. One patient may visit two or 
more different types of medical facility. Some patients may 
be duplicated in the disposition and medical facility variables.
Estimation of South Korea Economic Cost Due to Stroke
In 2015, Korea’s economic cost due to stroke was 7.4728 
trillion KRW (US$6.855 billion): That for ischemic stroke 
was 3.9874 trillion KRW (US$3.658 billion) while that for 
hemorrhage stroke was 3.4853 trillion KRW (US$3.197 
billion). The economic cost for ischemic stroke was 53.36% of 
the total stroke cost, and 502.0 billion KRW (US$460 million) 
more than that for hemorrhagic stroke. Among the total 
economic costs due to stroke, the share of lost productivity 
due to premature death was 45.53% with the highest portion, 
followed by inpatient/outpatient treatment cost (26.93%), loss 
of work (10.73%), and medication cost (5.09%) (Table 2).
Table 1. General Characteristics of Stroke Case in 2015  (N = 515 848)
Variables Category
Stroke cases
No. %
Gender
Male 277 641 46.18
Female 238 207 53.82
Age
0-9 657 0.13
10-19 575 0.11
20-29 1465 0.28
30-39 5558 1.08
40-49 24 243 4.70
50-59 78 878 15.29
60-69 128 542 24.92
70-79 178 504 34.60
80+ 97 426 18.89
Dispositiona
Hospitalization 129 513 21.52
Outpatient visits 472 371 78.48
Medical facilitya
Tertiary hospital 187 263 31.85
General hospital 232 450 39.54
Hospital 102 535 17.44
Clinic 63 863 10.86
Public health center, etc 1833 0.31
ICD-10
Ischemic stroke (163) 463 147 89.78
Hemorrhagic stroke (161) 52 701 10.22
Abbreviation: ICD-10, International Classification of Disease-10 version.
a Some patients may be duplicated.
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Direct Cost
Direct costs include inpatient cost, outpatient cost, non-
covered care cost, medication cost and cost for using the 
pharmacy, and the cost of assistive devices cost and the total 
direct cost for stroke was 32 684 trillion KRW (US$2.998 
billion): For ischemic stroke, it was 2.4987 trillion KRW 
(US$2.292 billion) while it was 769.7 billion KRW (US$706 
million) for hemorrhagic stroke. The direct medical cost 
for stroke was 2.8838 trillion KRW (US$2.645 billion): 
For ischemic stroke, it was 2.1988 trillion KRW (US$2.017 
million) while it was 685.0 billion KRW (US$628 million) for 
hemorrhage stroke; the former was about 3.2 times higher. 
The direct non-medical cost for stroke was 384.6 billion KRW 
(US$320 million): For ischemic stroke, it was 299.9 billion 
KRW (US$257 million) while it was 84.6 billion KRW (US$72 
million) for hemorrhage stroke, the former being around 
3.6 times higher. Direct cost represented 43.73% of the total 
economic cost for stroke. Inpatient and outpatient cost was 
26.93% with the highest share (Table 2).
Indirect Cost
Indirect cost is the sum of the losses due to lost work and 
premature death, and the indirect cost for stroke was 4.2043 
trillion KRW (US$3.857 billion): For ischemic stroke, it was 
1.4886 trillion KRW (US$1.365 billion) while for hemorrhagic 
stroke it was 2.7156 trillion KRW (US$2.491 billion), 1.8 
higher than that for ischemic stroke. For indirect cost due 
to stroke, loss of income was 3.4023 trillion KRW (US$3121 
million), loss of work was 802 billion KRW (US$687 million), 
respectively, with income loss due to premature death was 4.5 
times higher (Table 2). 
Estimation of Costs Per Stroke Event
The average economic cost per stroke case was about 7.9 
million KRW (US$7247): While the cost for ischemic 
stroke cases was 6.7 million KRW (US$6146), the cost for 
hemorrhage stroke cases was 18.5 million KRW (US$16 972), 
2.8 times as much as that in ischemic stroke cases (Table 3).
Discussion 
This study was conducted to estimate the scale and the nature 
of economic damage due to stroke with the intention that it 
be used as an evidential source for determining the efficient 
allocation of limited medical resources, and to support the 
development of policies concerning the prevention and 
management of the disease by estimating the scope of the 
economic cost of South Korea stroke cases in 2015, and an 
average annual economic cost per stroke case.
For patients with stroke treated in South Korea medical 
facilities using NHI in 2015, male patients outnumbered 
female patients, and the 70 to 79 age group ranked highest. 
Regarding disposition, the outpatient cases were about 3.6 
times more frequent than those requiring hospitalization. 
For primary medical facilities used by the patients, general 
hospitals showed the highest share, followed by advanced 
general hospitals and then standard hospitals followed in 
order. The type of stroke that occurred most frequently was 
ischemic stroke, about 8.8 times more often than hemorrhagic 
stroke. About 71% of all stroke cases use tertiary and general 
hospitals in Korea, compared to the case of Australia where 
hospitals and nursing homes are primarily used.15 In the 
majority of the developed countries, the demand for acute 
care beds is decreasing while demands for long-term care are 
greatly increasing, while the situation in Korea is different 
from other countries.16
In Korea, demands for long-term care is also dramatically 
increasing without requiring active treatment, and despite the 
preference in South Korea for hospitalized care even in cases 
where outpatient disposition or nursing home care would be 
sufficient, and the lack of long-term care facilities, the costs of 
Table 2. Economic Costs of Stroke in South Korea, 2015 – Unit: 1 million won (%)
Cost items Subcategory Ischemic Stroke % Hemorrhagic Stroke % Stroke %
Direct costs
Direct medical 
costs (1)
Inpatient costs 1 378 782 34.58 519 458 14.90 1 898 241 25.40
Outpatient costs 99 382 2.49 14 903 0.43 114 285 1.53
Non-covered care costs 263 113 6.60 91 375 2.62 354 489 4.74
Medication costs 335 280 8.41 45 409 1.30 380 689 5.09
Assistive devices costs 122 270 3.07 13 913 0.40 136 183 1.82
Total medical costs (1) 2 198 827 55.15 685 058 19.65 2 883 887 38.58
Direct non-
medical costs (2)
Transportation costs 57 387 1.44 8924 0.26 66 312 0.89
Caregiver’s costs 242 573 6.08 75 720 2.17 318 293 4.26
Total direct non-medical costs (2) 299 961 7.52 84 644 2.43 384 606 5.15
Total direct costs (1) + (2) 2 498 788 62.67 769 702 22.08 3 268 493 43.73 
Indirect costs
Lost productivity due to premature death (3) 881 203 22.10 2 521 126 72.33 3 402 329 45.53
Lost productivity due to hospitalization and 
outpatient visits (4)
607 442 15.23 194 562 5.58 802 005 10.73
Total indirect costs (3) + (4) 1 488 646 37.33 2 715 689 77.91 4 204 334 56.26 
Total costs (1) + (2) + (3) + (4) 3 987 434 100 3 485 391 100 7 472 828 100
Table 3. Costs Per Stroke Event, 2015           
Detailed Items Ischemic Stroke Hemorrhage Stroke Stroke
Costs per stroke case
(1 million kwn)
6.7 18.5 7.9
Abbreviation: kwn, Korean won.
Cha
International Journal of Health Policy and Management, 2018, 7(10), 904–909908
using the facilities appear low. Therefore, in order to establish 
policies related to stroke in Korea, it is necessary to take 
measures to reduce the burden of cost due to unnecessary 
hospitalization through the rearrangement of medical 
personnel and improvement of facilities.17
Among the entire economic burden due to stroke, income 
loss due to premature death was highest, followed, in order, 
by the cost for inpatient and outpatient care, the cost for work 
loss, cost for medication, and the cost for using pharmacies. 
By examining the differences in allocation of cost for each 
type of stroke as identified by the study, recommendations for 
the allocation of medical resources to address stroke can be 
made. In the case of hemorrhagic stroke with a large share 
of the premature death cost, the lethality rate was higher 
while the direct medical costs represented a high portion 
of the cost. For ischemic stroke, the lethality rate was lower, 
but the treatment required high-priced medical devices and 
procedures. This implies that a different strategy is required 
to reduce economic burden depending on whether it is 
hemorrhagic or ischemic stroke that is being addressed.
In Kang et al,18 which examined the calculation of the medical 
cost of stroke in Korea in 2004, for brain hemorrhage inpatient 
cost was 48.06 billion KRW (US$42 million) and outpatient 
cost was 6.16 billion KRW (US$5 million), a total sum of 54.24 
billion KRW (US$47 million). For ischemic stroke, inpatient 
cost was 135.9 billion KRW (US$118 million) and outpatient 
cost was 94.68 billion KRW (US$82 million), a total sum of 
230.62 billion KRW (US$201 million). This figure represented 
0.04% of the Korean gross domestic product (GDP) of US$680 
billion in 2004. In Lim et al,1 about the estimation of COI for 
strokes occurring in 2005, the economic burden was about 
3.7370 trillion KRW (US$3.267 billion) and the medical cost 
was about 1.1218 trillion KRW (US$980 million), 2.2% of 
the total healthcare cost in Korea in 2005. Ten years later, in 
2015, Korean GDP was 1.5586 quadrillion KRW (US$1.336 
trillion), and the 7.4728 trillion KRW (US$6.855 million), 
economic burden for stroke was 0.48% of the Korean GDP, 
and stroke treatment costs represented 13.77% of total medical 
costs covered by healthcare, 58.170 trillion KRW (US$49.787 
billion). As a result, despite the differences in the monetary 
value and healthcare situations in 2015 from those about 10 
years earlier, stroke has become a huge economic burden.
The reason was ischemic stroke cases, which numbered 8.8 
times more than hemorrhagic stroke cases. Direct costs were 
43.73% of the total economic burden and indirect costs were 
56.26%. The reason that Korea has lower direct costs was that 
the costs of medical insurance were lower, causing a relatively 
lower share of direct costs.19 This implies that hemorrhagic 
stroke, in spite of lower morbidity, is a disease with the greater 
economic burden for the individual, and the priority in the 
prevention of stroke can be different depending whether the 
subjects are the entire nation or individuals. 
In the study about cost according to use of resources by 
patients registered in the department of neurology in 
Philipps-Universität Marburg, Germany, the cost per patient 
was 3020 euros (US$3229) for ischemic stroke and 5080 euros 
(US$5432) for hemorrhage stroke. When including the cost 
of inpatient and rehabilitation after acute period, the cost was 
9880 euros (US$10 565) per patient. In a Taiwanese study, 
using the results of research on direct costs for 360 patients 
for treatment of their first ischemic stroke with acute origin, 
the length of stay (LOS) was 7 days (range: 1-121 days), and 
the cost per patient was 26 326 NTD (New Taiwan Dollars, 
US$841). The amount spent per day for one patient was 3777 
NTD (US$121).20
In this study, comparison with other countries in the medical 
disposition of stroke case is difficult, as a matter of fact. 
This is because of differences in demographic structure, 
the occurrence of stroke, and the compensation system are 
different, and these factors affect patients’ medical disposition 
and the status of medical suppliers’ use of medical and 
non-medical resources. For comparison, it is necessary to 
have standardized results about the status of patients, the 
current status of use of medical resources by type, and their 
effects.17
In Korea, the systematic medical rehabilitation system for 
stroke patients is still insufficient.21 The introduction and 
application of systems such as stroke units (SU) and early 
supported discharge (ESD) are necessary to reduce costs and 
improve resource utilization. In SU, an organized hospitalized 
service, teams from diverse disciplines are provided. There has 
been an increasing body of evidence suggesting the efficacy of 
SU in reducing mortality and morbidity.22 ESD is a system of 
the early discharge of mild and moderate stroke patients to a 
rehabilitation hospital in the community as soon as possible 
under government supervision.23 ESD has the benefit of 
minimizing the financial burdens on of patients and society 
while also bringing medical benefits.24
Regarding the limitations of the study; first, costs related 
to recreation and psychological pains were not included. 
Recently, in addition to direct costs, various indirect costs such 
as the cost of purchasing assistive devices, modifying housing 
facilities, and lost productivity of a patient, or patient’s care-
giving family member, and other caregiver costs are being 
taken into consideration.25 Second, the cost of using long-
term care insurance for the stroke patients was not included, 
and then the cost may be underestimated. In future studies, by 
including long-term care insurance service for the aged used 
by patients who have suffered strokes, it is expected that more 
accurate estimation can be made. Third, this study used the 
employment rate statistics of the whole population, not those 
of stroke cases. Fourth, it is thought that the indirect cost is 
less than the actual cost. This is because the life expectancy 
of the stroke patients decreases according to the disability 
level, which was not reflected in the productivity loss. Fifth, 
the data used in this study are limited in that secondary or 
tertiary diagnostics cannot be confirmed. Finally, there is a 
limitation to this study as it addresses not lifetime cost but 
annual costs. Also, it does not include all stroke survivors but 
those who utilize the health service, which can be listed in 
the insurance claim data.26 Thus, it is not a prevalence, nor 
incidence-based data. 
Conclusion
In Korea, the entire citizenry is insured by national health 
service, and a single base of insurance claim data has been 
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established, which provides very good conditions for 
conducting studies to estimate COI. This study estimated the 
scale of the economic burdens for stroke cases in Korea, and 
the average annual economic burden per stroke case, and is 
expected to provide an evidential source for use in determining 
policies on insurance for the disease and for setting priorities 
and making plans for arranging medical sources as well as to 
determine priorities for the effective prevention of stroke and 
national healthcare policies.
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